SK286513B6 - Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva - Google Patents

Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva Download PDF

Info

Publication number
SK286513B6
SK286513B6 SK1011-2003A SK10112003A SK286513B6 SK 286513 B6 SK286513 B6 SK 286513B6 SK 10112003 A SK10112003 A SK 10112003A SK 286513 B6 SK286513 B6 SK 286513B6
Authority
SK
Slovakia
Prior art keywords
hypertension
medicament
treatment
compound
formula
Prior art date
Application number
SK1011-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK10112003A3 (sk
Inventor
Paulus Wohlfart
Teri Suzuki
Ramalinga M. Dharanipragada
Alena Safarova
Armin Walser
Hartmut Strobel
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of SK10112003A3 publication Critical patent/SK10112003A3/sk
Publication of SK286513B6 publication Critical patent/SK286513B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1011-2003A 2001-02-13 2002-02-12 Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva SK286513B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102852 2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en) 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (2)

Publication Number Publication Date
SK10112003A3 SK10112003A3 (sk) 2004-01-08
SK286513B6 true SK286513B6 (sk) 2008-12-05

Family

ID=8176423

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1011-2003A SK286513B6 (sk) 2001-02-13 2002-02-12 Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva

Country Status (34)

Country Link
US (3) US6617359B2 (xx)
EP (1) EP1361882B1 (xx)
JP (1) JP4317689B2 (xx)
KR (1) KR101017531B1 (xx)
CN (1) CN100553631C (xx)
AT (1) ATE344669T1 (xx)
AU (1) AU2002253009B2 (xx)
BG (1) BG66065B1 (xx)
BR (1) BR0207178A (xx)
CA (1) CA2437966C (xx)
CY (1) CY1106278T1 (xx)
CZ (1) CZ20032154A3 (xx)
DE (1) DE60215919T2 (xx)
DK (1) DK1361882T3 (xx)
EE (1) EE05302B1 (xx)
ES (1) ES2274025T3 (xx)
HK (1) HK1062140A1 (xx)
HR (1) HRP20030646A2 (xx)
HU (1) HUP0302845A3 (xx)
IL (2) IL157208A0 (xx)
MX (1) MXPA03006841A (xx)
MY (1) MY135778A (xx)
NO (1) NO333522B1 (xx)
NZ (1) NZ527469A (xx)
PE (1) PE20020884A1 (xx)
PL (1) PL363452A1 (xx)
PT (1) PT1361882E (xx)
RS (1) RS51645B (xx)
RU (1) RU2308946C2 (xx)
SI (1) SI1361882T1 (xx)
SK (1) SK286513B6 (xx)
TW (1) TWI241190B (xx)
WO (1) WO2002064146A1 (xx)
ZA (1) ZA200305412B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1554240B1 (en) 2002-10-21 2009-05-06 Janssen Pharmaceutica N.V. Substituted tetralins and indanes and their use
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
DE602004011348T2 (de) * 2003-07-03 2009-01-08 Eli Lilly And Co., Indianapolis Indanderivate als muscarinrezeptoragonisten
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
JP2007511536A (ja) * 2003-11-17 2007-05-10 バイオマリン ファーマシューティカル インコーポレイテッド 代謝障害の処置のための方法及び組成物
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
WO2006055833A2 (en) * 2004-11-19 2006-05-26 Children's Hospital Medical Center Gtpase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en) 2005-02-18 2006-08-24 Francois Chianese Shoulder bushing for saw blades
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7795101B2 (en) * 2006-04-03 2010-09-14 United Microelectronics Corp. Method of forming a MOS transistor
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) * 2006-12-05 2014-01-10 (주)아모레퍼시픽 지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
AU2008311053B2 (en) * 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2011272800B2 (en) 2010-06-30 2016-11-03 Cyclerion Therapeutics, Inc. sGC stimulators
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN109384778B (zh) 2013-03-15 2022-12-13 赛克里翁治疗有限公司 化合物或其药学上可接受的盐在制备治疗疾病、健康病状或病症的药物上的应用
EA032028B1 (ru) 2013-12-11 2019-03-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
JP6624616B2 (ja) 2014-09-17 2019-12-25 サイクレリオン・セラピューティクス，インコーポレーテッド ｓＧＣ刺激剤
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
KR102513343B1 (ko) 2016-07-07 2023-03-22 사이클리온 테라퓨틱스, 인크. sGC 자극제의 인 전구약물
BR112019000293A2 (pt) 2016-07-07 2019-04-16 Ironwood Pharmaceuticals, Inc. formas sólidas de um estimulador de sgc

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) * 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
JP2003534377A (ja) * 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
US6812253B2 (en) 2004-11-02
NO20033546D0 (no) 2003-08-11
HRP20030646A2 (en) 2005-06-30
RS51645B (en) 2011-10-31
WO2002064146A1 (en) 2002-08-22
EE200300368A (et) 2003-10-15
KR101017531B1 (ko) 2011-02-28
RS61703A (xx) 2006-12-15
NZ527469A (en) 2005-04-29
RU2003127750A (ru) 2005-03-10
BR0207178A (pt) 2004-03-30
DK1361882T3 (da) 2007-03-12
US20050054729A1 (en) 2005-03-10
US20030022939A1 (en) 2003-01-30
AU2002253009B2 (en) 2006-09-14
RU2308946C2 (ru) 2007-10-27
US6617359B2 (en) 2003-09-09
US7202278B2 (en) 2007-04-10
HUP0302845A2 (hu) 2003-12-29
EE05302B1 (et) 2010-06-15
HK1062140A1 (en) 2004-10-21
KR20030074809A (ko) 2003-09-19
BG66065B1 (bg) 2011-01-31
IL157208A0 (en) 2004-02-19
NO20033546L (no) 2003-09-24
PE20020884A1 (es) 2002-11-25
CY1106278T1 (el) 2011-10-12
MY135778A (en) 2008-06-30
NO333522B1 (no) 2013-07-01
EP1361882B1 (en) 2006-11-08
CA2437966A1 (en) 2002-08-22
JP2004518713A (ja) 2004-06-24
BG107994A (bg) 2004-08-31
CN1496264A (zh) 2004-05-12
US20040019114A1 (en) 2004-01-29
DE60215919D1 (de) 2006-12-21
SI1361882T1 (sl) 2007-02-28
MXPA03006841A (es) 2003-11-13
DE60215919T2 (de) 2007-05-31
JP4317689B2 (ja) 2009-08-19
HUP0302845A3 (en) 2005-11-28
PL363452A1 (en) 2004-11-15
CN100553631C (zh) 2009-10-28
ZA200305412B (en) 2004-09-02
ATE344669T1 (de) 2006-11-15
TWI241190B (en) 2005-10-11
PT1361882E (pt) 2007-01-31
IL157208A (en) 2009-09-22
SK10112003A3 (sk) 2004-01-08
EP1361882A1 (en) 2003-11-19
ES2274025T3 (es) 2007-05-16
CA2437966C (en) 2011-06-14
CZ20032154A3 (cs) 2004-05-12

Similar Documents

Publication Publication Date Title
SK286513B6 (sk) Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva
AU2002253009A1 (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
JP4537653B2 (ja) アシル化１，２，３，４−テトラヒドロナフチルアミンおよび医薬としてのその使用
JP5618548B2 (ja) イミダゾ［１，２−ａ］ピリジンおよびそれらの薬剤としての使用
EP1534275B1 (en) Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
NO330011B1 (no) Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse for fremstilling av farmasoytiske midler,samt farmasoytisk preparat inneholdende minst en slik forbindelse
JP2004518720A (ja) アシル化６，７，８，９−テトラヒドロ−５ｈ−ベンゾシクロヘプテニルアミンおよび医薬としてのその使用
JP2010519321A (ja) イミダゾ［１，２−ａ］アジンおよびそれらの薬剤としての使用
PL210930B1 (pl) Acylowane arylocykloalkiloaminy, ich zastosowanie jako środków farmaceutycznych, preparat farmaceutyczny oraz zastosowanie tych związków do wytwarzania środka leczniczego
US20070066577A1 (en) Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
US8168665B2 (en) Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130212